Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
Neurocrine Biosciences (Nasdaq: NBIX) will host its third quarter 2022 financial results conference call and webcast on November 1, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q3 press release will be available earlier on the same day at 4:30 a.m. PT (7:30 a.m. ET). Investors can access the call via domestic 866-952-8559 or international 785-424-1881 dial-in numbers using conference ID NBIX. A replay will be available on the company’s website.
Neurocrine focuses on treatments for neurological and psychiatric disorders.
- Upcoming Q3 2022 financial results expected to provide insights into business performance.
- Access to live webcast and replay for investor engagement.
- None.
Conference Call and Webcast Scheduled for Tuesday, November 1
SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on November 1, 2022.
The schedule for the press release and conference call / webcast is as follows:
• Q3 2022 Press Release: | November 1, 2022 at 4:30 a.m. PT / 7:30 a.m. ET |
• Q3 2022 Conference Call: | November 1, 2022 at 5:00 a.m. PT / 8:00 a.m. ET |
• Domestic Dial-In Number: | 866-952-8559 |
• International Dial-In Number: | 785-424-1881 |
• Conference ID: | NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2022-financial-results-301645805.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences release its Q3 2022 financial results?
What time is the Neurocrine Biosciences conference call?
How can investors access the Neurocrine Biosciences webcast?
What is the conference ID for the Neurocrine Biosciences call?
